Survodutide: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 27 de julio de 2026

Survodutide (BI 456906; CAS 2805997-46-8) is a long-acting lipidated peptide designed as a dual agonist of the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It is studied in metabolic research models for its ability to combine incretin signaling with activation of the glucagon receptor. Material intended exclusively for research use.

Survodutide (English name Survodutide; development code BI 456906; CAS 2805997-46-8) is a long-acting synthetic peptide belonging to the class of incretin/glucagon coagonists. With molecular formula C192H289N47O61 and a molecular weight of approximately 4231.69 g/mol, it is an extended peptide chain structurally derived from the glucagon and GLP-1 backbones, into which a fatty-acid modification (acylation) has been incorporated, conferring reversible binding to serum albumin. This feature markedly prolongs its half-life in preclinical and clinical models, which has allowed weekly dosing regimens to be explored in research studies. Survodutide has been developed within a collaboration between Boehringer Ingelheim and Zealand Pharma, and conceptually belongs to the same family of dual-mechanism molecules that have driven recent interest in metabolic pharmacology.

From a structural standpoint, Survodutide is a long-chain peptide analog that retains the recognition determinants needed to simultaneously activate two class B G protein-coupled receptors: the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). The design of this type of co-agonist seeks to balance the relative potency at each receptor, so that the complementary effects of both pathways are combined. Acylation with a lipid chain, an approach also used in other long-acting incretin analogs, is the element that explains the plasma stability observed in research models.

The proposed mechanism of action is based on the dual and coordinated activation of both receptors. Through the GLP-1R arm, the molecule reproduces classic incretin signaling: in preclinical models, potentiation of glucose-dependent insulin secretion, slowing of gastric emptying, and modulation of hypothalamic circuits linked to satiety have been described. Through the GCGR arm, activation of the glucagon receptor is associated in animal models with an increase in energy expenditure and with effects on hepatic lipid metabolism, including the mobilization and oxidation of hepatic fat. The working hypothesis underpinning this class is that glucagon signaling contributes a component of energy expenditure and reduction of hepatic steatosis that complements the reduction in intake and the glycemic control attributable to the GLP-1 pathway, while the incretin component counteracts the hyperglycemic tendency that glucagon would have if administered in isolation. This balance is precisely the axis of research for the molecule.

Regarding the documented research applications, Survodutide has been the subject of studies in two major areas within metabolic research. The first is research on body-weight regulation and energy balance in obesity models, where the clinical program has already reached phase 3: in SYNCHRONIZE-1 (le Roux CW et al., N Engl J Med, June 7, 2026; PMID 42253238; NCT06066515), 725 adults with obesity, or with overweight and at least one related complication, without type 2 diabetes, received weekly subcutaneous survodutide titrated up to 3.6 mg or 6.0 mg, or placebo, and at week 76 the mean change in body weight was -12.2 % (3.6 mg) and -13.0 % (6.0 mg) versus -5.4 % with placebo. The second area of interest is research on metabolic steatotic liver disease (MASLD/MASH), where the glucagon receptor agonism component offers a mechanistic rationale for exploring the reduction of hepatic fat: in the phase 3 trial SYNCHRONIZE-MASLD (Kaplan LM et al., Nat Med, June 8, 2026; PMID 42252333), 216 adults with obesity and MASLD at risk received survodutide 6.0 mg weekly (n = 146) or placebo (n = 70) over 48 weeks, and the two co-primary endpoints were met: a reduction of at least 30% in liver fat measured by MRI-PDFF and percent change in body weight. Its profile on glycemic and lipid parameters has also been explored as secondary metabolic markers. All these uses must be understood strictly in the context of scientific research and controlled trials, not as established indications.

The level of evidence for Survodutide is more robust than that of most research peptides: in addition to the preclinical base that characterizes the dual mechanism, there are published results from two controlled phase 3 trials: SYNCHRONIZE-1 in obesity (N Engl J Med, June 2026; PMID 42253238) and SYNCHRONIZE-MASLD in metabolic dysfunction-associated steatotic liver disease (Nat Med, June 2026; PMID 42252333). Nevertheless, it is important to be honest about the state of knowledge: the molecule remains in clinical development, it does not constitute an approved therapy nor one of established use, and the long-term safety data continue to be consolidated. As occurs with the incretin/glucagon coagonist class, the gastrointestinal tolerability profile and the effects derived from glucagon receptor activation (for example on heart rate and metabolic parameters) are subject to ongoing surveillance and characterization in research. This datasheet is offered for informational and scientific reference purposes for researchers, and the compound is marketed solely for use in laboratory research.